Citi analyst Peter Verdult downgraded Genmab to Neutral from Buy with a price target of DKK 3,055, down from DKK 3,165, telling investors that he sees a more balanced risk/reward for 2023. While recent ASH datasets "reinforced the competitive profile" of Genmab-exposed assets, he is concerned that the market is over-emphasizing the importance of GEN3014 with timelines for head-to-head data versus Darzalex Faspro possibly slipping into 2024, said Verdult, who adds that datasets in 2023 are "likely to be incremental."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- Genmab to hold a virtual investor update
- Genmab announces results from multiple clinical trials evaluating epcoritamab
- Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
- Genmab price target raised to DKK 3,450 from DKK 2,900 at JPMorgan
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
